T. Rowe Price Associates’s Oric Pharmaceuticals ORIC Stock Holding History
Bought
Maintained
Sold
Other funds holding ORIC
SL
T. Rowe Price Associates's ORIC Position: Q3 2026 in Review
T. Rowe Price Associates reduced its Oric Pharmaceuticals (ORIC) stake by 23% in Q3 2026, selling an estimated $19M and leaving 5,088,495 shares worth $68.5M. The position accounts for 0.01% of the portfolio, ranked #760.
T. Rowe Price Associates first reported a position in ORIC in Q4 2021 and has held it in 20 quarters since. The position peaked at $71.7M in Q2 2026. 203 funds tracked by Wall St. Rank hold ORIC as of Q3 2026.
- T. Rowe Price Associates held 5,088,495 shares of Oric Pharmaceuticals worth $68.5M as of Q3 2026.
- T. Rowe Price Associates sold 1,529,059 Oric Pharmaceuticals shares in Q3 2026, an estimated $19M.
- Oric Pharmaceuticals made up 0.01% of T. Rowe Price Associates's portfolio in Q3 2026, its #760 holding.
- T. Rowe Price Associates first reported a position in Oric Pharmaceuticals in Q4 2021 and has held it in 20 quarters since.
- T. Rowe Price Associates's Oric Pharmaceuticals position peaked at $71.7M in Q2 2026.
- 203 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2026.
Based on T. Rowe Price Associates's 13F filing for Q3 2026, filed 16 Nov 2026.